CATALYST PHARMACEUTICALS, INC. — Director's Dealing 2023

Dec 14, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK: 0001369568
Period of Report: 2023-12-12

Reporting Person: Tierney David S (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-12-12	Common stock, par value $0.001 per share	M	50000	$1.13	Acquired	383541	Direct
2023-12-12	Common stock, par value $0.001 per share	S	50000	$13.325	Disposed	333541	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-12-12	Options to purchase common stock	$1.13	M	50000	Acquired	2024-01-03	Common Stock (50000)	Direct

Footnotes

F1: Shares were sold on the open market for personal reasons, and to fund the exercise price for stock options expiring on January 3, 2024, and not as a result of any disagreement with the Company.

F2: Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $13.30 to $13.36 per share.

F3: Options vested in three annual tranches beginning on January 3, 2018.